DL-norvaline → L-Leucine

HRID 372861

Reaktionsgleichung

[NH2:1][C@H:2]([C:7]([OH:9])=[O:8])[CH2:3][CH:4]([CH3:6])[CH3:5].NC(C(O)=O)CCC.[CH3:18][CH2:19][CH:20]1[O:37][C:35](=[O:36])[CH2:34][CH:33]([O:38]C(C)=O)[CH:32]([CH3:42])[CH:31]([O:43][CH:44]2[O:49][CH:48]([CH3:50])[CH:47]([O:51][CH:52]3[O:57][CH:56]([CH3:58])[CH:55]([OH:59])[C:54]([OH:61])([CH3:60])[CH2:53]3)[CH:46]([N:62]([CH3:64])[CH3:63])[CH:45]2[OH:65])[CH:30]([CH2:66][CH:67]=[O:68])[CH2:29][CH:28]([CH3:69])[C:26](=[O:27])[CH:25]=[CH:24][C:23]([CH3:70])=[CH:22][CH:21]1[CH2:71][O:72][CH:73]1[O:78][CH:77]([CH3:79])[CH:76]([OH:80])[CH:75]([O:81][CH3:82])[CH:74]1[O:83][CH3:84]>>[CH3:18][CH2:19][C@H:20]1[O:37][C:35](=[O:36])[CH2:34][C@@H:33]([OH:38])[C@H:32]([CH3:42])[C@@H:31]([O:43][C@@H:44]2[O:49][C@H:48]([CH3:50])[C@@H:47]([O:51][C@@H:52]3[O:57][C@@H:56]([CH3:58])[C@H:55]([OH:59])[C@@:54]([OH:61])([CH3:60])[CH2:53]3)[C@H:46]([N:62]([CH3:64])[CH3:63])[C@H:45]2[OH:65])[C@@H:30]([CH2:66][CH:67]=[O:68])[CH2:29][C@@H:28]([CH3:69])[C:26](=[O:27])[CH:25]=[CH:24][C:23]([CH3:70])=[CH:22][C@@H:21]1[CH2:71][O:72][C@@H:73]1[O:78][C@H:77]([CH3:79])[C@@H:76]([OH:80])[C@@H:75]([O:81][CH3:82])[C@H:74]1[O:83][CH3:84].[NH2:1][C@H:2]([C:7]([OH:9])=[O:8])[CH2:3][CH:4]([CH3:6])[CH3:5]

Komponenten

Edukt 3

HCID 824DL-norvaline

HCID 6106L-Leucine

HCID 64266063-Acetyltylosin

Produkt 2

HCID 6106L-Leucine

HCID 5280440Tylosin

Versuchsvorschrift

A similar cultivation and reaction as in Example 1 was carried out by substituting L-leucine as the isovaleryl donor for DL-norvaline. From 60 g of tylosin and 15 g of L-leucine, about 900 mg of white crystals of 4"-isovaleryltylosin and 17 g of white crystals of 3-acetyltylosin were obtained.

Aufarbeitung

customA similar cultivation and reaction as in Example 1

Quellen und Nachweise

ORD-Eintrag: ord-7adc09abdb89410da0581d1897206d85
Quelldatensatz: uspto-grants-1978_05
DOI: 10.6084/m9.figshare.5104873.v1
Patentnummer: US04092473

Verknüpfte Notizen

Wird geladen…